FDA approves treatment of non-small cell lung cancer
August 2011 Vol. 6 No. 8
Author: Jill A. Ritchey, BSN, MA
The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK) gene. Read more.